Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Has Consensus Target Price of $11.50

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $11.50.

Several equities analysts recently commented on the stock. Piper Sandler decreased their price objective on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Weiss Ratings upgraded Karyopharm Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Royal Bank Of Canada reissued an “outperform” rating and set a $16.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, July 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Karyopharm Therapeutics in a report on Tuesday, June 9th. Finally, Wall Street Zen cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th.

Institutional Trading of Karyopharm Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Commodore Capital LP acquired a new stake in shares of Karyopharm Therapeutics during the 1st quarter worth about $10,862,000. Avidity Partners Management LP raised its stake in shares of Karyopharm Therapeutics by 244.6% in the first quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after acquiring an additional 329,175 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Karyopharm Therapeutics by 75.9% in the 1st quarter. Renaissance Technologies LLC now owns 105,414 shares of the company’s stock valued at $587,000 after buying an additional 45,500 shares during the period. Squarepoint Ops LLC purchased a new position in Karyopharm Therapeutics in the second quarter worth approximately $623,000. Finally, Context Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth $464,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Price Performance

KPTI stock opened at $1.73 on Friday. The firm’s 50-day moving average is $2.98 and its 200 day moving average is $6.56. Karyopharm Therapeutics has a 12 month low of $1.24 and a 12 month high of $10.99. The company has a market capitalization of $39.24 million, a PE ratio of -0.13 and a beta of 0.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95). The firm had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $32.19 million. Sell-side analysts forecast that Karyopharm Therapeutics will post -4.7 EPS for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics, Inc is a commercial-stage pharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research centers on nuclear transport, particularly the role of exportin 1 (XPO1) in regulating the movement of proteins and RNA between a cell’s nucleus and cytoplasm.

Karyopharm’s primary product is selinexor, an oral selective inhibitor of XPO1. In the United States, selinexor is marketed as XPOVIO for certain patients with multiple myeloma and diffuse large B-cell lymphoma, in combination with specified therapies or under defined treatment circumstances.